IceCure Medical Ltd (NASDAQ:ICCM) Q2 2023 Earnings Conference Call August 14, 2023 10:00 AM ET
Company Participants
Todd Kehrli - EVC Group, Investor Relations
Eyal Shamir - Chief Executive Officer
Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer
Robert Ward - ProSense User, Assistant Professor, Diagnostic Imaging, Warren Alpert Medical School of Brown University and Program Director, Breast Imaging Fellowship, Associate Chief of Diagnostic Imaging at Women & Infants Hospital
Conference Call Participants
Anthony Vendetti - Maxim Group
Benjamin Haynor - Alliance Global Partners
Kemp Dolliver - Brookline Capital
Jake Sekelsky - H.C. Wainwright
Operator
Good morning and thank you for standing by. Currently, all participants are in a listen-only mode. After management's discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded.
I would now like to turn the conference over to Todd Kehrli. Please go ahead.
Todd Kehrli
Thank you, operator, and welcome to IceCure Medical's conference call to review the financial results for the first six months ended June 30, 2023 and to provide an update on recent operational highlights. Please refer to the earnings press release that we issued early this morning.
Participating on today's call are IceCure Medical's CEO, Eyal Shamir, and the company's CFO and COO, Ronen Tsimerman. Additionally, Dr. Robert Ward is joining the call today to share his experience using ProSense and will be available during the Q&A session, which will follow the prepared remarks.
Before we begin, I'd like to remind everyone that this call and the question-and-answer session that follows that contain forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws.
Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements in this presentation when we discuss the achievements, we expect to accomplish as we continue to advance our growth strategy, our positioning to make significant commercial advances in key markets, pursuit of regulatory approvals in various jurisdictions, expansion of clinical applications, release of results from our clinical trials, potential market adoption and future sales of IceCure's minimally invasive cryoablation technology, advancing regulatory and commercial strategies, strategic plans and our belief that we are well capitalized to execute on commercial opportunities to increase shareholder value.